Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: kha vu who wrote (54154)	8/1/1999 7:43:00 PM
From: kendall harmon	Respond to of 120523

CHRX--came out in some scans over the weekend, and now I find it on IBD's new america page for tomorrow. CS First Boston comments in midJuly CS First Boston (Begleiter, David PM CALL: CHRX: Strong 2Q99 Ahead Of Expectations. Raising Price Tgt To $42 FBC STRONG BUY SMALL CAP ChiRex (CHRX) Strong Second Quarter Ahead of Expectations. Raising Target Price to $42. Summary ChiRex reported strong second quarter earnings of $0.25, slightly ahead of our $0.24 estimate. A year ago the company earned $0.06. This is the fourth straight quarter ChiRex has beaten expectations. Over the past year management has substantially improved the quality of operations while at the same time significantly reducing costs. The highlight of the quarter was the development business, which posted sales growth of 142% to $7.5 million. In six months ChiRex has built a world-scale, fully integrated process development business. The process development business enhances the growth profile, earnings power and returns potential of ChiRex. As one of only few outsourcing companies to offer both contract process research and development and contract manufacturing of pharmaceutical ingredients, Chirex is unique.